Circulating immune complexes of Aβ and IgM in plasma of patients with Alzheimer's disease

Journal of Neural Transmission

Volumn 116, Issue 7, 2009, Pages 913-920

  Marcello, Andrea ^a   Wirths, Oliver ^a   Schneider Axmann, Thomas ^a   Degerman Gunnarsson, Malin ^b   Lannfelt, Lars ^b   Bayer, Thomas A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

A ; Alzheimer's disease; Biomarkers; Immune complexes; Plasma

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

AGED; ALZHEIMER DISEASE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL FILTRATION; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN DETERMINATION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIGEN-ANTIBODY COMPLEX; BIOLOGICAL MARKERS; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 67651172813     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-009-0224-y     Document Type: Article

References (59)

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders-DSM-IV, 4th edn. American Psychiatric Association, Washington
2. N Andreasen L Minthon P Davidsson E Vanmechelen 2001 Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice Arch Neurol 58 3 373 379
3. L Beneduce F Castaldi M Marino N Tono 2004 Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes Int J Biol Markers 19 2 155 159
4. L Beneduce F Castaldi M Marino S Quarta 2005 Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma Cancer 103 12 2558 2565
5. L Beneduce T Prayer-Galetti AM Giustinian A Gallotta 2007 Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients Cancer Detect Prev 31 5 402 407
6. L Beneduce G Pesce A Gallotta F Zampieri 2008 Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma Eur J Clin Invest 38 8 571 577
7. AL Biere B Ostaszewski ER Stimson BT Hyman 1996 Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma J Biol Chem 271 51 32916 32922
8. K Blennow 2004 Cerebrospinal fluid protein biomarkers for Alzheimer's disease NeuroRx 1 2 213 225
9. F Castaldi M Marino L Beneduce C Belluco 2005 Detection of circulating CEA-IgM complexes in early stage colorectal cancer Int J Biol Markers 20 4 204 208
10. F Castaldi M Marino L Beneduce C Belluco 2005 Detection of circulating CEA-IgM complexes in early stage colorectal cancer Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma Int J Biol Markers 20 4 204 208
11. RB DeMattos KR Bales DJ Cummins JC Dodart 2001 Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc Natl Acad Sci USA 98 15 8850 8855
12. R Dodel H Hampel C Depboylu S Lin 2002 Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease Ann Neurol 52 2 253 256
13. Y Du R Dodel H Hampel K Buerger 2001 Reduced levels of amyloid beta-peptide antibody in Alzheimer disease Neurology 57 5 801 805
14. H Fukumoto M Tennis JJ Locascio BT Hyman 2003 Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels Arch Neurol 60 7 958 964
15. D Galasko L Chang R Motter CM Clark 1998 High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype Arch Neurol 55 7 937 945
16. V Geylis V Kourilov Z Meiner I Nennesmo 2005 Human monoclonal antibodies against amyloid-beta from healthy adults Neurobiol Aging 26 5 597 606
17. V Giedraitis J Sundelof MC Irizarry N Garevik 2007 The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease Neurosci Lett 427 3 127 131
18. NR Graff-Radford JE Crook J Lucas BF Boeve 2007 Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease Arch Neurol 64 3 354 362
19. MA Gruden TB Davudova M Malisauskas VV Zamotin 2004 Autoimmune responses to amyloid structures of Abeta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease Dement Geriatr Cogn Disord 18 2 165 171
20. MA Gruden TB Davidova M Malisauskas RD Sewell 2007 Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta(25-35) oligomers, S100b and neurotransmitters J Neuroimmunol 186 1-2 181 192
21. J Hardy DJ Selkoe 2002 The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 5580 353 356
22. C Hock U Konietzko JR Streffer J Tracy 2003 Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 4 547 554
23. BT Hyman C Smith I Buldyrev C Whelan 2001 Autoantibodies to amyloid-beta and Alzheimer's disease Ann Neurol 49 6 808 810
24. M Jensen J Schroder M Blomberg B Engvall 1999 Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression Ann Neurol 45 4 504 511
25. M Kanai E Matsubara K Isoe K Urakami 1998 Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan Ann Neurol 44 1 17 26
26. T Kawarabayashi M Shoji 2008 Plasma biomarkers of Alzheimer's disease Curr Opin Psychiatry 21 3 260 267
27. H Kessler FG Pajonk D Bach T Schneider-Axmann 2008 Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial J Neural Transm 115 12 1651 1659
28. T Kosaka M Imagawa K Seki H Arai 1997 The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43) Neurology 48 3 741 745
29. YM Kuo TA Kokjohn W Kalback D Luehrs 2000 Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma Biochem Biophys Res Commun 268 3 750 756
30. YM Kuo TA Kokjohn W Kalback D Luehrs 2000 Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma Biochem Biophys Res Commun 268 3 750 756
31. P Lewczuk H Esselmann M Otto JM Maler 2004 Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau Neurobiol Aging 25 3 273 281
32. E Matsubara J Ghiso B Frangione M Amari 1999 Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome Ann Neurol 45 4 537 541
33. Y Matsumoto D Yanase M Noguchi-Shinohara K Ono 2007 Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease Dement Geriatr Cogn Disord 23 4 241 245
34. PL McGeer EG McGeer 2001 Inflammation, autotoxicity and Alzheimer disease Neurobiol Aging 22 6 799 809
35. G McKhann D Drachman M Folstein R Katzman 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 7 939 944
36. PD Mehta T Pirttila 2005 Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease Neurodegener Dis 2 5 242 245
37. PD Mehta T Pirttila SP Mehta EA Sersen 2000 Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease Arch Neurol 57 1 100 105
38. PD Mehta T Pirttila BA Patrick M Barshatzky 2001 Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease Neurosci Lett 304 1-2 102 106
39. A Nath E Hall M Tuzova M Dobbs 2003 Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development Neuromolecular Med 3 1 29 39
40. UE Nydegger 2007 Immune complex pathophysiology Ann N Y Acad Sci 1109 66 83
41. M Pesaresi C Lovati P Bertora E Mailland 2006 Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment Neurobiol Aging 27 6 904 905 (Pubitemid 44287903)
42. N Pomara LM Willoughby JJ Sidtis PD Mehta 2005 Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report Am J Geriatr Psychiatry 13 10 914 917
43. JL Price JC Morris 1999 Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 3 358 368
44. VK Singh 1997 Neuroautoimmunity: pathogenic implications for Alzheimer's disease Gerontology 43 1-2 79 94
45. J Sundelof V Giedraitis MC Irizarry J Sundstrom 2008 Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study Arch Neurol 65 2 256 263
46. N Suzuki TT Cheung X-D Cai A Odaka 1994 An increased percentage of long amyloid β protein is secreated by familial amyloid β protein precursor (βAPP717) mutants Science 264 1336 1340
47. A Tamaoka T Fukushima N Sawamura K Ishikawa 1996 Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease J Neurol Sci 141 1-2 65 68
48. T Tapiola T Pirttila PD Mehta I Alafuzofff 2000 Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease Neurobiol Aging 21 5 735 740
49. E Tarkowski N Andreasen A Tarkowski K Blennow 2003 Intrathecal inflammation precedes development of Alzheimer's disease J Neurol Neurosurg Psychiatry 74 9 1200 1205
50. K Trieb G Ransmayr R Sgonc H Lassmann 1996 APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease Neurobiol Aging 17 4 541 547
51. JQ Trojanowski JH Growdon 1998 A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research J Neuropathol Exp Neurol 57 6 643 644
52. M van Oijen A Hofman HD Soares PJ Koudstaal 2006 Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study Lancet Neurol 5 8 655 660
53. H Vanderstichele E Van Kerschaver C Hesse P Davidsson 2000 Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma Amyloid 7 4 245 258
54. ME Weksler N Relkin R Turkenich S LaRusse 2002 Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals Exp Gerontol 37 7 943 948
55. B Winblad K Palmer M Kivipelto V Jelic 2004 Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment J Intern Med 256 3 240 246
56. JM Woulfe R Duke JM Middeldorp S Stevens 2002 Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD Neurology 58 9 1435 1436
57. S Xu F Gaskin 1997 Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease Mech Ageing Dev 94 1-3 213 222
58. W Xu T Kawarabayashi E Matsubara K Deguchi 2008 Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls Brain Res 1219 169 179
59. H Yamaguchi S Sugihara A Ogawa N Oshima 2001 Alzheimer beta amyloid deposition enhanced by apoE epsilon4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects J Neuropathol Exp Neurol 60 7 731 739